Why the study?
Flow diverters carry high thromboembolic risk and standard DAPT with aspirin and clopidogrel has reduced efficacy due to clopidogrel resistance, prompting evaluation of short-term tirofiban combined with DAPT.
Does adding short-term tirofiban to DAPT reduce thromboembolic events or increase bleeding risk in patients with unruptured intracranial aneurysms treated with flow diverters?
Does adding short-term tirofiban to DAPT reduce thromboembolic events or increase bleeding risk in patients with unruptured intracranial aneurysms treated with flow diverters?
Adding short-term tirofiban to DAPT after flow diverter placement for intracranial aneurysms appears safe but does not significantly reduce thromboembolic events compared to DAPT alone.
Short-term tirofiban addition appears safe without excess bleeding after FD placement; leaves open efficacy gains over DAPT alone pending randomized trials.
Background Flow diverters (FDs) are increasingly applied for intracranial aneurysms, but their high metal coverage raises thromboembolic risk. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard, yet clopidogrel resistance, especially in Asian populations, reduces efficacy. Tirofiban, a glycoprotein IIb/IIIa inhibitor, may enhance perioperative protection. This study evaluated the safety and efficacy of adding short-term tirofiban to DAPT after FDs treatment and developed a model to predict thromboembolic events (TEEs). Methods We retrospectively analyzed 319 patients with unruptured aneurysms treated with FDs across multiple centers (2018–2022). Patients received either DAPT alone (group 1) or DAPT plus tirofiban (group 2). After propensity score matching (140 per group), ischemic and hemorrhagic complications were compared. Predictive factors for TEEs were identified using Lasso-logistic regression, and a nomogram was constructed. Results A total of 389 aneurysms in 319 patients were included in the statistical analysis. There were no statistically significant differences in the baseline characteristics of the patients and aneurysms between the groups, indicating comparability. After PSM, 140 patients were included in each group for comparison. The group 1 vs. the group 2 (Early postoperative complications): TEEs (3.6% vs. 5.0%, p = 0.768), intracranial hemorrhage (0% vs. 0.7%, p = 0.390); The group 1 vs. the group 2 (Long-term postoperative complications): TEEs (3.3% vs. 5.7%, p = 0.370), intracranial hemorrhage (3.6% vs. 1.4%, p = 0.444), and peripheral bleeding events (2.9% vs. 6.5%, p = 0.256) showed no statistically significant differences. Multivariable logistic regression identified maximum aneurysm diameter (OR = 1.153, 95% CI: 1.087–1.223, p < 0.0001) as significant risk factor for TEEs, while diameter of the feeding artery (OR = 0.442, 95% CI: 0.286–0.682, p = 0.0003) was protective factor. A nomogram based on these factors achieved a C-index of 0.723. Conclusion Tirofiban combined with DAPT in flow diverter treatment for intracranial aneurysms demonstrated good safety without increasing bleeding risk, though its efficacy advantage over DAPT alone was not evident. The proposed nomogram enables individualized TEE risk prediction and supports personalized antiplatelet management.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: